Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset N0) non-oat cell lung cancer - PubMed (original) (raw)

. 1984 Nov;88(5 Pt 1):659-62.

• PMID: 6492836

Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset N0) non-oat cell lung cancer

P I Tartter et al. J Thorac Cardiovasc Surg. 1984 Nov.

Abstract

Recent studies suggest that pretransplant blood transfusions prolong kidney graft survival by nonspecific immune suppression. Since immune suppression in patients with cancer is associated with early recurrence and poor prognosis, we studied the relationship of perioperative blood transfusion to recurrence of Stage I (subset N0) lung cancer. Technique-related variables were minimized by limiting the study to one surgeon (P. A. K.). Life-table and Cox proportional hazards analysis of age, sex, tumor size, histopathology, admission and discharge hematocrit values, estimated operative blood loss, duration of operation, extent of resection, anesthetic agents, and blood transfusion revealed two statistically significant prognostic factors: extent of resection (p = 0.0056) and use or non-use of transfusions (p = 0.0283). The cumulative 5 year disease-free survival rate of the 15 patients undergoing pneumonectomy was 42% compared to 75% for 150 patients undergoing lobectomy and lesser procedures. Transfused patients had lower disease-free rates within 5 years than nontransfused patients (62% versus 76%, p = 0.0132). Survival advantage was also noted in nontransfused patients after deleting patients subjected to pneumonectomy. These results indicate that perioperative transfusion in patients with lung cancer undergoing resection accelerates the appearance of recurrent or metastatic cancer. This supports the findings of previous studies of breast and colon cancer that blood transfusion is detrimental to the patient with cancer.

PubMed Disclaimer

Similar articles

• Perioperative blood transfusion has prognostic significance for breast cancer.
  Tartter PI, Burrows L, Papatestas AE, Lesnick G, Aufses AH Jr. Tartter PI, et al. Surgery. 1985 Feb;97(2):225-30. Surgery. 1985. PMID: 3969625
• Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer.
  Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Lardinois D, et al. Ann Thorac Surg. 2005 Jul;80(1):268-74; discussion 274-5. doi: 10.1016/j.athoracsur.2005.02.005. Ann Thorac Surg. 2005. PMID: 15975380
• Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.
  El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, Urda SJ, Luketich JD, Landreneau RJ. El-Sherif A, et al. Ann Thorac Surg. 2006 Aug;82(2):408-15; discussion 415-6. doi: 10.1016/j.athoracsur.2006.02.029. Ann Thorac Surg. 2006. PMID: 16863738
• Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients?
  Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Chamogeorgakis T, et al. Interact Cardiovasc Thorac Surg. 2009 Mar;8(3):364-72. doi: 10.1510/icvts.2008.178947. Epub 2008 Jul 18. Interact Cardiovasc Thorac Surg. 2009. PMID: 18641014 Review.
• The present status of surgery for lung cancer.
  Lacquet LK. Lacquet LK. Acta Chir Belg. 1996 Nov-Dec;96(6):245-51. Acta Chir Belg. 1996. PMID: 9008764 Review.

Cited by

• The effect of lung cancer on cytokine expression in peripheral blood mononuclear cells.
  Chang DH, Rutledge JR, Patel AA, Heerdt BG, Augenlicht LH, Korst RJ. Chang DH, et al. PLoS One. 2013 Jun 6;8(6):e64456. doi: 10.1371/journal.pone.0064456. Print 2013. PLoS One. 2013. PMID: 23762239 Free PMC article.
• Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice.
  Shirwadkar S, Blajchman MA, Frame B, Singal DP. Shirwadkar S, et al. J Cancer Res Clin Oncol. 1992;118(3):176-80. doi: 10.1007/BF01410130. J Cancer Res Clin Oncol. 1992. PMID: 1548281
• Perioperative blood transfusions and survival in patients with non-small cell lung cancer: a retrospective study.
  Cata JP, Chukka V, Wang H, Feng L, Gottumukkala V, Martinez F, Vaporciyan AA. Cata JP, et al. BMC Anesthesiol. 2013 Nov 15;13(1):42. doi: 10.1186/1471-2253-13-42. BMC Anesthesiol. 2013. PMID: 24228905 Free PMC article.
• Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases.
  Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Kooby DA, et al. Ann Surg. 2003 Jun;237(6):860-9; discussion 869-70. doi: 10.1097/01.SLA.0000072371.95588.DA. Ann Surg. 2003. PMID: 12796583 Free PMC article.
• Blood transfusions may adversely affect survival outcomes of patients with lung cancer: a systematic review and meta-analysis.
  Cho S, Park J, Lee M, Lee D, Choi H, Gim G, Kim L, Kang CY, Oh Y, Viveiros P, Vagia E, Oh MS, Cho GJ, Bharat A, Chae YK. Cho S, et al. Transl Lung Cancer Res. 2021 Apr;10(4):1700-1710. doi: 10.21037/tlcr-20-933. Transl Lung Cancer Res. 2021. PMID: 34012786 Free PMC article.

MeSH terms

LinkOut - more resources

• Medical

  • MedlinePlus Health Information